A new generation of philanthropists, whose wealth was created via entrepreneurship in technology-driven fields, has the unique opportunity to make a real difference in speeding the pace of progress in the fight against cancer. Not content with having hospital pavilions named for them or with giving large, open-ended gifts for academic research, they want to use their wealth to have a direct and visible impact on patients’ health. Research we have conducted has revealed a variety of new, highly impactful investment approaches that can help accelerate the pace of the development, approval, and commercialization of new cancer therapies. By embracing these new approaches this new generation of philanthropists has the opportunity to truly help cure cancer.
People tend to fear the wrong things when it comes to indexing and exchange-traded funds. Take the recent hand-wringing over an Index Industry Association report that there are now 3.7 million market indexes, an increase of about a half a million from last year. The Twitter commentary was predictable, with observations such as “peak passive” and “smells like CDOs.
BOSTON — Cold weather this week didn’t matter to the crowds at the AI World conference here, as activity around artificial intelligence continues to heat up. Over three days, more than 2,200 attendees learned about the latest advances in machine learning, deep learning, and the industries being affected by AI.
Andrew W. Lo é um autor prolífico. Professor de finanças na Sloan School of Management, do Massachusetts Institute of Technology (MIT), ganhou reconhecimento do público, por causa de seu livro A non-random walk down Wall Street ( Uma caminhada não aleatória por Wall Street , sem edição em português), e dos profissionais, por seus artigos em periódicos importantes de finanças e economia. Lo conquistou muitos prêmios em sua carreira.
Thus far, 2018 has proven to be a prosperous year for many in the industry, thanks in no small part to the strength of the U.S. economy.
And while economists are predicting a slowdown in growth next year, the next 12 months, barring unforeseeable incidents, should remain strong, with few signs of a pullback on the horizon.
"The economy is clearly strong," said Andrew Lo, a professor at MIT's Sloan School of Management and director of the MIT Laboratory for Financial Engineering. "We've got pretty low unemployment, very reasonable inflation, and all eyes are on the stock market, which has done quite well. I think, overall, both in the United States and more broadly around the world, things are going quite well. In that kind of an environment, it's no wonder people are confident about the future and willing to spend money on things like vacation and travel."
At its worst, finance leads to crises and economic dislocation and, yet, it's absolutely vital to solving many of the problems society faces today. MIT's Andrew W Lo introduces some of the best books on finance and explains how it can change the world for the better.
At the height of the credit crunch in 2008, academics at the London School of Economics were infamously caught off guard when the Queen of England asked why no one saw the financial crisis coming. Now, 10 years after the collapse of Lehman Brothers Holdings Inc. on Sept. 15, 2008, economists, regulators, policymakers and finance industry insiders are asking themselves where the next financial crisis could come from, and what danger signals they should watch for, to avoid being blindsided again.
While there are several areas of potential concern, industry experts broadly do not believe a systemic collapse on the same scale of 2008 is on the horizon.
If your house is on fire, what is the plan? Head for the exit, naturally. But if a market crash is burning a big hole in your investment portfolio, selling out may not be the best course of action. The very same emotions and biases that can lead to good decisions in many areas of daily life can lead us astray in matters of money, experts say.
Statisticians use it. Non-statisticians have heard of it (likely in the context of the standard threshold of p = 0.05). While it’s not the only component of a clinical trial design, the p-value helps determine the maximum acceptable level of uncertainty associated with clinical evidence and, in a way, the fate of patient access to a new medical device.
But, is the traditional 0.05 threshold too restrictive for the patient populations willing to accept more uncertainty, depriving them of treatment options? Is it too permissive for other patient populations? Can we optimize clinical trial design by considering patients’ urgency for new therapeutic options, as well as their willingness to accept uncertainty?